Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386415583> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4386415583 endingPage "322841" @default.
- W4386415583 startingPage "bjo" @default.
- W4386415583 abstract "To describe the effectiveness and side-effect profile of adding difluprednate therapy to patients with anterior scleritis being treated systemically.Retrospective chart review. Charts from all patients with anterior scleritis who were treated with topical difluprednate in addition to systemic therapy from 1 January 2018 to 1 January 2020 were reviewed. Data collected included: demographics, scleritis type, systemic diagnosis, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, type of systemic treatment used, best-corrected visual acuity (BCVA) and lens status. The primary outcome was clinical resolution of scleritis. Secondary outcomes included BCVA loss ≥2 lines, change in lens status or cataract surgery and IOP ≥24 mm Hg.Thirty-two patients (44 eyes) were analysed. The median age was 57 years (IQR 52, 72); 59% were female; 72% were Caucasian. An associated systemic disease was present in 59%. Systemic therapies used when difluprednate was added were: 65% immunosuppressive agents, 43% prednisone and 25% non-steroidal anti-inflammatory drugs. The addition of difluprednate resulted in clinical resolution in 79.6% of the treated eyes. Median time to inactivity was 9 weeks (IQR 5, 20). Eyes initially using 2-4 drops per day had a higher response rate (89%, p=0.005). Over a median follow-up of 34 weeks (IQR 21, 74), 11 eyes had IOP elevation; 6 eyes lost ≥2 lines of BCVA, 5 eyes had cataract progression.Most eyes treated with difluprednate achieved inactivity. The addition of difluprednate to systemic therapies provides an alternative to achieve control of inflammation." @default.
- W4386415583 created "2023-09-05" @default.
- W4386415583 creator A5062196360 @default.
- W4386415583 creator A5064879712 @default.
- W4386415583 creator A5074048612 @default.
- W4386415583 creator A5074396794 @default.
- W4386415583 date "2023-09-04" @default.
- W4386415583 modified "2023-10-16" @default.
- W4386415583 title "Effectiveness of difluprednate in addition to systemic therapy for the treatment of anterior scleritis" @default.
- W4386415583 cites W1966772950 @default.
- W4386415583 cites W1974162532 @default.
- W4386415583 cites W2006142366 @default.
- W4386415583 cites W2006699106 @default.
- W4386415583 cites W2014175731 @default.
- W4386415583 cites W2030314563 @default.
- W4386415583 cites W2035244366 @default.
- W4386415583 cites W2037162457 @default.
- W4386415583 cites W2045952946 @default.
- W4386415583 cites W2055913604 @default.
- W4386415583 cites W2063340779 @default.
- W4386415583 cites W2067260112 @default.
- W4386415583 cites W2074159405 @default.
- W4386415583 cites W2112356750 @default.
- W4386415583 cites W2116724316 @default.
- W4386415583 cites W2137903085 @default.
- W4386415583 cites W2141351444 @default.
- W4386415583 cites W2170282519 @default.
- W4386415583 cites W2326254244 @default.
- W4386415583 cites W3199962948 @default.
- W4386415583 doi "https://doi.org/10.1136/bjo-2022-322841" @default.
- W4386415583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37666642" @default.
- W4386415583 hasPublicationYear "2023" @default.
- W4386415583 type Work @default.
- W4386415583 citedByCount "0" @default.
- W4386415583 crossrefType "journal-article" @default.
- W4386415583 hasAuthorship W4386415583A5062196360 @default.
- W4386415583 hasAuthorship W4386415583A5064879712 @default.
- W4386415583 hasAuthorship W4386415583A5074048612 @default.
- W4386415583 hasAuthorship W4386415583A5074396794 @default.
- W4386415583 hasConcept C118487528 @default.
- W4386415583 hasConcept C141071460 @default.
- W4386415583 hasConcept C167135981 @default.
- W4386415583 hasConcept C2775888743 @default.
- W4386415583 hasConcept C2776194053 @default.
- W4386415583 hasConcept C2777100477 @default.
- W4386415583 hasConcept C2778257484 @default.
- W4386415583 hasConcept C2778720950 @default.
- W4386415583 hasConcept C2781053147 @default.
- W4386415583 hasConcept C2781092963 @default.
- W4386415583 hasConcept C71924100 @default.
- W4386415583 hasConceptScore W4386415583C118487528 @default.
- W4386415583 hasConceptScore W4386415583C141071460 @default.
- W4386415583 hasConceptScore W4386415583C167135981 @default.
- W4386415583 hasConceptScore W4386415583C2775888743 @default.
- W4386415583 hasConceptScore W4386415583C2776194053 @default.
- W4386415583 hasConceptScore W4386415583C2777100477 @default.
- W4386415583 hasConceptScore W4386415583C2778257484 @default.
- W4386415583 hasConceptScore W4386415583C2778720950 @default.
- W4386415583 hasConceptScore W4386415583C2781053147 @default.
- W4386415583 hasConceptScore W4386415583C2781092963 @default.
- W4386415583 hasConceptScore W4386415583C71924100 @default.
- W4386415583 hasLocation W43864155831 @default.
- W4386415583 hasLocation W43864155832 @default.
- W4386415583 hasOpenAccess W4386415583 @default.
- W4386415583 hasPrimaryLocation W43864155831 @default.
- W4386415583 hasRelatedWork W1973588800 @default.
- W4386415583 hasRelatedWork W2089782499 @default.
- W4386415583 hasRelatedWork W2347673534 @default.
- W4386415583 hasRelatedWork W2362959154 @default.
- W4386415583 hasRelatedWork W2375014553 @default.
- W4386415583 hasRelatedWork W2375782316 @default.
- W4386415583 hasRelatedWork W2793502828 @default.
- W4386415583 hasRelatedWork W2970312644 @default.
- W4386415583 hasRelatedWork W3144440816 @default.
- W4386415583 hasRelatedWork W4378977707 @default.
- W4386415583 isParatext "false" @default.
- W4386415583 isRetracted "false" @default.
- W4386415583 workType "article" @default.